Mithra Pharmaceuticals S.A.

Report Publication Announcement • Mar 2, 2023

Mithra to host webcast for 2022 financial results on 7 March 2023

Liege, Belgium, 2 March 2023 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces that it will host a live webcast on Tuesday, 7 March 2023 at 09:00 CET to present its 2022 financial and operating results.

The live webcast can be accessed on the Mithra website or by clicking here. A replay of the webcast will be available on the Mithra investor's website shortly after the close of the call.

********

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 – investorrelations@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle® , Mithra is now focusing on its second product Donesta® , the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

ESTELLE® , DONESTA® and MYRING® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

News Alerts

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

LinkedIn • Twitter • Facebook